Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease.
Collier
D J
DJ
Clinical Pharmacology, St Bartholomew's and the Royal London School of Medicine, Charterhouse Square, London EC1M 6BQ, UK. d.j.collier@mds.qmw.ac.uk
Bernardi
L
L
Angell-James
J E
JE
Caulfield
M J
MJ
Sleight
P
P
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017311:Amlodipine / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D017704:Baroreflex / Q000502:physiology*; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology*; D004232:Diuretics / Q000627:therapeutic use; D004311:Double-Blind Method; D004562:Electrocardiography / Q000379:methods; D006339:Heart Rate / Q000502:physiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality* / Q000503:physiopathology*; D016032:Randomized Controlled Trials as Topic
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017311:Amlodipine